CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AZITHROMYCI	ASSAY/	*USPNF 2021*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	In *Solution A*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N FOR ORAL SUSPENSION	*Procedure*	*ISSUE 1*						Change orthophosphoric acid to: phosphoric acid
CARBOPROST TROMETHAMINE	CHEMICAL INFORMATION	*USP43–NF38*	771	30-Apr-2021	1-May-2021	*NA*	*NA*	Change 489.64 to: 489.65 AND Change (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-Dihydroxy-2-[(*E*)-(3*S*)-3-hydroxy-3-methyl-1-octenyl]cyclopentyl]-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); to: (*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-Dihydroxy-2-[(*E*)-(3*S*)-3-hydroxy-3-methyloct-1-enyl]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								cyclopentyl]-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1);
SERTRALINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	26-Mar-2021	1-May-2021	*NA*	*NA*	In USP Sertraline Hydrochloride Racemic Mixture RS: Change $C_{17}H_{17}Cl_2 \cdot HCl$ to: $C_{17}H_{17}Cl_2N \cdot HCl$
RILUZOLE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	3883	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Riluzole Related Compound A RS: Change 4-Trifluoromethoxyaniline. $C_7H_6F_3NO$ 177.12 to: 4-(Trifluoromethoxy)aniline. $C_7H_6F_3NO$ 177.13
MIRTAZAPINE	ADDITIONAL R	*USP43–NF38*	Online	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	EQUIREMENTS/*USP Reference Standards <11>*							Mirtazapine Resolution Mixture RS: Change Impurity D: 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine. to: Impurity D: [Note–This impurity may be available either as the free base form or as the hydrochloride salt form.] 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine or 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]pyri do[2,3-*c*][2]benzazepine hydrochloride.
PACKAGING AND STORAGE REQUIREMENTS	GENERAL *Packaging Definitions*	*Second Supplement to USP43–NF38*	Online	26-Mar-2021	1-Dec-2025	*NA*	*NA*	In *Light-resistant container*: Change ?661.2?, *Functionality, Spectral Transmission Requirements for Light-Resistant Components and Systems.* to: ?661.2?, *Functionality Test Method, Spectral Transmission Requirements for Light-Resistant Components and Systems*.
GENERAL NOTICES AND REQUIREMEN	2. OFFICIAL STATUS AND LEGAL	*USPNF 2021 ISSUE 1*	Online	26-Mar-2021	1-May-2021	*NA*	*NA*	In *2.10. Official Text*: Change http://www.uspn

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TS	RECOGNITION							f.com. to: https://online.uspnf.com.
CARBOMER COPOLYMER	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	26-Mar-2021	1-May-2021	*NA*	*NA*	See online.uspnf.com for correction
GLYBURIDE AND METFORMIN HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	2128	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Glyburide Related Compound A RS: Change 368.84 to: 368.83
AMPICILLIN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	316	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Amoxicillin Related Compound A RS: Change (2*S*,5*R*,6*R*)-6-Amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. $C_{16}H_{14}N_2O_2$ 266.29 to: (2*S*,5*R*,6*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-6-Amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. $C_8H_{12}N_2O_3S$ 216.26
TRIHEXYPHENIDYL HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities*	*USP43–NF38*	4519	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In *Sample solution*: Change Nominally 1 mg/mL of trihexyphenidyl hydrochloride in *Diluent* prepared as follows. to: Nominally 1 mg/mL of trihexyphenidyl hydrochloride prepared as follows.
RILUZOLE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	3882	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Riluzole Related Compound A RS: Change 4-Trifluoromethoxyphenylamine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								; 4-trifluoromethoxyanaline. $C_7H_6F_3NO$ 177.12 to: 4-(Trifluoromethoxy)aniline. $C_7H_6F_3NO$ 177.13
MIRTAZAPINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Mirtazapine Resolution Mixture RS: Change Impurity D: 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine. to: Impurity D: [Note–This impurity may be available either as the free base form or as the hydrochloride salt form.] 1,2,3,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine or 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine hydrochloride.
PACKAGING AND STORAGE REQUIREMENTS	GENERAL *Packaging Definitions*	*Second Supplement to USP43–NF38*	Online	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In *Light-resistant container*: Change ?671?, *Spectral Transmission* to: ?671?, *Spectral Transmission for Light-Resistant Packaging Components or Systems*
NADOLOL AND BENDROFLUMETHIAZIDE	IMPURITIES	*USPNF 2021 ISSUE 1*	Online	26-Mar-2021	1-May-2021	*NA*	*NA*	In *Organic Impurities, Procedure 2: Be*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS								*ndroflumethiazide Related Impurities/Acceptance criteria*: Change The reporting threshold is NMT 0.05%. to: The reporting threshold is 0.05%.
ZILEUTON	*USP Reference standards <11>*	*USP43–NF38*	4679	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Zileuton Related Compound A RS: Change *N* -(1-Benzo-[*b*]thien-2-ylethyl) urea. $C_{11}H_{12}N_2OS$ 220.30 to: *N* -(1-Benzo-[*b*]thien-2-ylethyl) urea; Also known as 1-[1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-(Benzo[*b*]thiophen-2-yl)ethyl]urea. $C_{11}H_{12}N_2OS$ 220.29 AND In USP Zileuton Related Compound B RS: Change 2-(Benzo[*b*]thien-2-oyl)benzo[*b*]thiopene. $C_{17}H_{10}OS_2$ 294.40 to: 2-(Benzo[*b*]thien-2-oyl)benzo[*b*]thiophene; Also known as Bis(benzo[*b*]thiophen-2-yl)methanone. $C_{17}H_{10}OS_2$ 294.39 AND In USP Zileuton

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Related Compound C RS: Change 1-Benzo-[*b*]thien-2-ylethanone. $C_{10}H_8OS$ 176.24 to: 1-Benzo-[*b*]thien-2-ylethanone; Also known as 1-(Benzo[*b*]thiophen-2-yl)ethan-1-one. $C_{10}H_8OS$ 176.23
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	26-Feb-2021	1-Mar-2021	*NA*	*NA*	In USP Amlodipine Related Compound A RS: Change 522.93 to: 522.94
STRONTIUM CHLORIDE Sr	CHEMICAL INFORMATION	*USP43–NF38*	4126	26-Feb-2021	1-Mar-2021	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
89 INJECTION								$^{89}SrC1^{2}$ to: $^{89}SrCl_{2}$
FENTANYL CITRATE	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	Change 528.59 to: 528.60
PACLITAXEL INJECTION	TITLE	*USPNF 2021 ISSUE 1*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	Change Paclit 1axel Injection to: Paclitaxel Injection
TOTAL ORGANIC CARBON	PROCEDURES */2. Sterile Water*	*USPNF 2021 ISSUE 1*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	In Column 2 in *Table 2*: Change 1,4-Benzoquinone (mL/L) to: 1,4-Benzoquinone (mg/L) AND In Column 2 and 4 in *Table 3*: Change Sucrose Concentration (mg/mL) to: Sucrose Concentration

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mg/L)
COPOVIDONE	IM PURITIES/*Limit of Monomers (1-Vinyl-2-Pyrrolidone and Vinyl Acetate)*	*Harmonization (1 2021)*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	In *Standard solution*: Change 0.25 ?g/mL of 1-vinyl-2-pyrrolidone and 5 ?g/mL of vinyl acetate, respectively, diluted from the *Standard stock solution* in *Mobile phase* to: 0.25 ?g/mL of 1-vinyl-2-pyrrolidone and 0.25 ?g/mL of vinyl acetate, respectively, diluted from the *Standard stock solution* in *Mobile phase*
AMITRIPTYLINE HYDROCHLORIDE	ASSAY/*Procedure*	*USP43–NF38*	261	26-Feb-2021	1-Mar-2021	*NA*	*NA*	In *System suitability solution*: Change 0.5 µg/mL of USP Amitriptyline

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Related Compound A RS, 1 µg/mL of USP Amitriptyline Hydrochloride RS, and 1.5 µg/mL each of USP Amitriptyline Related Compound B RS, USP Cyclobenzaprine Hydrochloride RS, and USP Nortriptyline Hydrochloride RS from suitable volumes of *Standard solution*, *System suitability stock solution A*, and *System suitability stock solution B* in *Mobile phase* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.5 µg/mL of USP Amitriptyline Related Compound A RS, 1 µg/mL of USP Amitriptyline Hydrochloride RS, and 1.5 µg/mL each of USP Amitriptyline Related Compound B RS, USP Cyclobenzaprine Hydrochloride RS, and USP Nortriptyline Hydrochloride RS from suitable volumes of *System suitability stock solution A* and *System suitability stock solution B* in *Mobile phase*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	4598	26-Feb-2021	1-Mar-2021	*NA*	*NA*	In *Test 2/Analysis*: Change Result$_i$ = (r_U/r_S) × C_S × (M_{r1}/M_{r2}) to: Result$_i$ = (A_U/A_S) × C_S × (M_{r1}/M_{r2}) AND Change r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* to: A_U = absorbance from the *Sample solution* A_S = absorbance from the *Standard solution*
FENTANYL CITRATE	IMPUR	*USPNF 2021 ISSUE 1*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	In both variable definition lists in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/*Organic Impurities*							*Analysis*: Change M_{r1} = molecular weight of fentanyl citrate, 528.59 M_{r2} = molecular weight of fentanyl, 336.47 to: M_{r1} = molecular weight of fentanyl citrate, 528.60 M_{r2} = molecular weight of fentanyl, 336.48
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	Online	26-Feb-2021	1-Mar-2021	*NA*	*NA*	In the first variable definition list in *Analysis*: Change 522.93 to: 522.94
CLONIDINE	ADDITIONAL R EQUIREMENT S/*USP Reference Standards <11>*	*USP43–NF38*	1100	26-Feb-2021	1-Mar-2021	*NA*	*NA*	In USP Clonidine Related Compound A RS: Change 1-Acetyl-2-(2,6-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dichlorophenylamino)-2-(4,5-dihydroimidazol). to: 1-Acetyl-2-(2,6-dichlorophenylimino)imidazolidine.
CLOZAPINE	IM IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	In *System suitability/Suitability requirements/Resolution*: Change NLT 2.5 between demethyl clozapine and clozapine to: NLT 2.5 between demethyl clozapine and clozapine, *System suitability solution*
CLEANING GLASS APPARATUS	CLEANING VALIDATION BEST PRACTICES	*USPNF 2021 ISSUE 1*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	Change *Quantitative Assessment of Cleaning*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Procedure to: *Quantitative Assessment of Cleaning Process*
ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—PARTICLE COUNTING VIA LIGHT SCATTERING	4. FACTORS THAT AFFECT THE TESTING	*Second Supplement to USP43–NF38*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	In paragraph 1: Change an airborne liquid counter. to: an airborne counter.
FEXOFENADINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	1869	29-Jan-2021	1-Feb-2021	*NA*	*NA*	In USP Fexofenadine Related Compound B RS: Change 3-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl benzeneacetic acid hydrochloride. $C_{32}H_{39}NO_4$ · HCl 538.12 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl benzeneacetic acid hydrochloride monohydrate; Also known as 2-(3-{1-Hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid hydrochloride monohydrate. $C_{32}H_{39}NO_4 \cdot HCl \cdot H_2O$ 556.14
HYDROMORPHONE HYDROCHLORIDE ORAL SOLUTION	IMPURITIES/*Organic Impurities*	*USP43–NF38*	2252	29-Jan-2021	1-Feb-2021	*NA*	*NA*	In footnote g of *Table 3*: Change 2,2?-Bihydromorphone. to: (5?)-3-Hydroxy-2-[(5?)-3-hydroxy-17-methyl-6-o

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								xo-4,5-epoxymorphinan-2-yl]-17-methyl-4,5-epoxymorphinan-6-one dihydrochloride.
RISKS AND MITIGATION STRATEGIES FOR THE STORAGE AND TRANSPORTATION OF FINISHED DRUG PRODUCTS	4. RISK MITIGATION CATEGORIES AS QMS ELEMENTS	*Second Supplement to USP43–NF38*	Online	29-Jan-2021	1-Feb-2021	*NA*	*NA*	In *4.1 Documentation and Procedures*/*4.1.3 Labels*: Change The use of symbols that are recognized by international organizations is strongly recommended. to: The use of symbols that are recognized by international organizations is strongly recommended. See *General Notices, 10.20. Labeling*.
DOPAMINE HY	*Limit of 5-hydro*	*USP43–NF38*	1495	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Cation-*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROCHLORIDE AND DEXTROSE INJECTION	*xymethylfurfural and related substances*							*exchange column*: Change Proceed as directed under *Column Partition Chromatography* (see *Chromatography* ?621?), to: Proceed as directed under *Chromatography* ?621?, *General Procedures*, *Column Chromatography*,
CARVEDILOL	IM PURITIES/*Organic Impurities, Procedure 2*	*USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Table 3*/footnote b: Change 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(6,7,8,9-tetrahydro-5*H*-carbazol-4-yloxy)propan-2-ol. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydro-1*H*-carbazol-5-yloxy)propan-2-ol.
NOREPINEPHRINE BITARTRATE	IDENTIFICATION/*C. Procedure*	*USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Sample solution*: Change 0.01 µg/mL to: 0.1 mg/mL
ELASTOMERIC COMPONENT FUNCTIONAL SUITABILITY IN PARENTERAL PRODUCT PACKAGING/DELIVERY SYSTEMS	5. NEEDLE AND SPIKE ACCESS FUNCTIONAL SUITABILITY TESTS	*Second Supplement to USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In paragraph 4 of *5.1 Fragmentation/Cartridge systems/Procedure A*: Change graticlule to: graticule
PINDOLOL TABLETS	ASSAY/*Procedure*	*Second Supplement to USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Chromatographic system*/*Run time*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								NLT 2 times the retention time of the nortriptytine peak to: NLT 2 times the retention time of the nortriptyline peak
FENTANYL	CHEMICAL INFORMATION	*USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	Change 336.47 to: 336.48
DOBUTAMINE IN DEXTROSE INJECTION	ASSAY/ *Procedure 1: Dextrose*	*USP43–NF38*	1470	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Analysis*: Change Result = [(100 × *a*) × (*I*/?)] × (1/C_U) × (M_{r1}/M_{r2}) × 100 to: Result = [(100 × *a*)/(*I* × ?)] × (1/C_U) × (M_{r1}/M_{r2}) × 100
CARVEDILOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards*	*USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In USP Carvedilol Related Compound A RS: Change 629.74 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								629.75 AND In USP Carvedilol Related Compound B RS: Change 645.74 to: 645.76 AND In USP Carvedilol Related Compound C RS: Change 496.60 to: 496.61 AND In USP Carvedilol Related Compound E RS: Change 2-(2-Methoxyphenoxy)ethylamine. $C_9H_{13}NO_2$ 167.21 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								[Note—This material may be available in the free base or salt form.] 2-(2-Methoxyphenoxy)ethylamine. $C_9H_{13}NO_2$ 167.21 2-(2-Methoxyphenoxy)ethylamine hydrochloride monohydrate. $C_9H_{13}NO_2$? HCl ? H_2O 221.68 AND In USP Carvedilol System Suitability Mixture RS: Change Mixture of approximately 0.1% carvedilol related compound F (1-(2-(2-Methoxyphenoxy)ethylam

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ino)-3-(2,3,4,9-tetra hydro-1*H*-carbazol-5-yloxy)propan-2-ol) in a matrix of carvedilol drug substance. to: Contains a mixture of carvedilol related compound F in a matrix of carvedilol drug substance: Carvedilol. Carvedilol related compound F. [Note—This material may be available in the free base or salt form.] 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydr

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								o-1*H*-carbazol-5-yloxy)propan-2-ol. $C_{24}H_{30}N_2O_4$ 410.51 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydro-1*H*-carbazol-5-yloxy)propan-2-ol acetate. $C_{24}H_{30}N_2O_4$? $C_2H_4O_2$ 470.57
NALOXONE HYDROCHLORIDE INJECTION	IMPURITIES/*Limit of 2,2?-Bisnaloxone*	*Revision Bulletin (Official September 01, 2020)*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Analysis*: Change [Note—The relative retention times for naloxone and 2,2?-bisnaloxone (4,5?:4?,5?-diepoxy-3,3?,14,14?-tetrahydroxy-17,17?-bis(prop-2-enyl)-2,2?-bimorphinanyl-6,6?-dione) are 1.0 and 2.8,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								respectively.] to: [Note—The relative retention times for naloxone and 2,2?-bisnaloxone (4,5?:4?,5??-diepoxy-3,3?,14,14?-tetrahydroxy-17,17?-bis(prop-2-enyl)-2,2?-bimorphinanyl-6,6?-dione) are 1.0 and 2.8, respectively.]
FENTANYL CITRATE INJECTION	*Assay*	*USP43–NF38*	1849	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Procedure*: Change
								$CD(r_U/r_S)$ in which 336.48 and 528.59 are the molecular weights to:
								CD(*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{U}/r_{S}$) in which 336.48 and 528.60 are the molecular weights
TRYPSIN	CHEMICAL INFORMATION	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Change $C_{1012}H_{1555}N_{279}O_{324}S_{14}$ 23,293 (for bovine ?-Trypsin) to: $C_{1012}H_{1585}N_{279}O_{324}S_{14}$ 23,293 (for bovine ?-Trypsin)
TIAGABINE HYDROCHLORIDE	ASSAY/ *Procedure*	*USP43–NF38*	4365	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the *Standard solution*: Change Transfer suitable volumes of the *Standard stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluent to volume. to: 0.1 mg/mL of USP Tiagabine Hydrochloride RS and 0.04 mg/mL of butylparaben in *Diluent* prepared as follows. Transfer suitable volumes of the *Standard stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. AND In the *Sample solution*: Change Transfer suitable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volumes of the *Sample stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. to: 0.1 mg/mL of Tiagabine Hydrochloride and 0.04 mg/mL of butylparaben in *Diluent* prepared as follows. Transfer suitable volumes of the *Sample stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluent to volume.
AMIODARONE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Amiodarone Related Compound H RS: Change 2-Chloro-*N*,*N*-diethylethanamine. $C_6H_{14}ClN$ 135.64 to: 2-Chloro-*N*,*N*-diethylethanamine hydrochloride. $C_6H_{14}ClN \cdot HCl$ 172.09
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION	1. PRELIMINARY ASSESSMENT	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In paragraph 4 of *1.4 Choosing an apparatus*: Change peak vessels to: apex vessels
PLASTIC MATERIALS OF CONSTRU	POLYAMIDE 6	*First Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Related Substances/*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CTION								*Chromatographic system*/*Column*: Change 0.25-mm × 0.25-µm; phase G25 to: 30-m × 0.25-mm; 0.25-µm phase G25
ORBIFLOXACIN	*Related compounds*	*USP43–NF38*	3275	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Procedure*: Change $20{,}000(C_S)(r_i/r_S)(1/F)$ in which C_S is the concentration, in mg per mL, of orbifloxacin in the *Standard solution*; r_i is the peak area response for each impurity obtained from the *Test solution*; r_S is the peak area response for the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								orbifloxacin peak obtained from the *Standard solution*; and *F* is the relative response factor for each impurity, as presented in *Table 1*. to: $20{,}000(C_S)(r_i/r_S)(1/F)(1/W)$ in which C_S is the concentration, in mg per mL, of orbifloxacin in the *Standard solution*; r_i is the peak area response for each impurity obtained from the *Test solution*; r_S is the peak area response for the orbifloxacin peak obtained

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								from the *Standard solution*; *F* is the relative response factor for each impurity, as presented in *Table 1*; and *W* is the sample weight taken to prepare the *Test solution* (mg).
GOSERELIN ACETATE	IMPURITIES/*Organic Impurities: Related Compounds*	*Interim Revision Announcement (Official May 01, 2020)*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Table 1*: Change Goserelinare to: Goserelin

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10

- Page 11
- Page 12
- Page 13
- Page 14
- …
- Next page Next ›
- Last page Last »